Belgium and the Netherlands have agreed to reimburse Biogen’s orphan drug Spinraza (nusinersen) following joint health technology assessment and joint pricing negotiations as part of the BeNeLuxA collaboration. The news marks the first time the coalition has reached a positive joint reimbursement decision and will likely show that such collaboration on pricing and reimbursement is viable and could encourage more countries to sign up.
Spinraza, for the treatment of spinal muscular atrophy, will be available from Aug. 1 in the Netherlands and Sept. 1...